Literature DB >> 24448750

High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study.

Marina Degoricija1, Marijan Situm, Jelena Korać, Ana Miljković, Katarina Matić, Martina Paradžik, Ivana Marinović Terzić, Ana Jerončić, Snježana Tomić, Janoš Terzić.   

Abstract

PURPOSE: Given that the tumor-promoting inflammation has been previously established in squamous cell carcinoma of the bladder but its contribution to development of urothelial carcinoma (UC) still remains elusive, our aim was to study changes in expression and activity of inflammation-mediating NF-κB and STAT3 transcription factors in human urothelial bladder carcinoma as well as expression of their target genes cyclin D1, VEGFA and TGFβ1.
METHODS: Gene expression of STAT3, NF-κB, TGFβ1, cyclin D1 and VEGFA was measured by quantitative real-time polymerase chain reaction in both tumor and healthy bladder tissue from 36 patients with UC of the bladder. Activation of STAT3 and NF-κB was assessed with immunohistochemistry and immunoblot.
RESULTS: Urothelial bladder carcinoma displayed elevated expression as well as activation of NF-κB (P = 5.38e-10) and STAT3 (P = 0.002) transcription factors. Furthermore, elevated level of expression was observed for cyclin D1, VEGFA and TGFβ1 (P = 9.71e-09, P = 9.71e-09, P = 5.38e-10). Preliminary statistical analysis indicated that the level of upregulation of STAT3 or NF-κB was probably not dependent upon the grade (P = 0.984 and 0.803, respectively) and invasiveness of the tumor (0.399 and 0.949), nor to the gender (0.780 and 0.536) and age (0.660 and 0.816) of the patients.
CONCLUSIONS: NF-κB and STAT3 signaling pathways, as main inflammatory mediators, are found to be activated in urothelial bladder carcinoma indicating that chronic inflammatory processes are accompanying development of this tumor type. Future studies will have to determine possible causative role of inflammatory processes in development of urothelial bladder carcinomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24448750     DOI: 10.1007/s00345-014-1237-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  28 in total

1.  Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.

Authors:  Philip Levy Ho; Erica Julianne Lay; Weiguo Jian; Diana Parra; Keith Syson Chan
Journal:  Cancer Res       Date:  2012-04-24       Impact factor: 12.701

2.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

3.  Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.

Authors:  I E Eder; A Stenzl; A Hobisch; M V Cronauer; G Bartsch; H Klocker
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

4.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

Authors:  J P Crew; T O'Brien; M Bradburn; S Fuggle; R Bicknell; D Cranston; A L Harris
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

5.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Authors:  Guilian Niu; Kenneth L Wright; Mei Huang; Lanxi Song; Eric Haura; James Turkson; Shumin Zhang; Tianhong Wang; Dominic Sinibaldi; Domenico Coppola; Richard Heller; Lee M Ellis; James Karras; Jacqueline Bromberg; Drew Pardoll; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

Review 6.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

7.  Urothelial dysplasia and inflammation induced by Schistosoma haematobium total antigen instillation in mice normal urothelium.

Authors:  Mónica C Botelho; Paula A Oliveira; Carlos Lopes; José M Correia da Costa; José C Machado
Journal:  Urol Oncol       Date:  2009-11-27       Impact factor: 3.498

8.  Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.

Authors:  Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Journal:  Urol Oncol       Date:  2007 Nov-Dec       Impact factor: 3.498

9.  Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder.

Authors:  Georgia Levidou; Angelica A Saetta; Penelope Korkolopoulou; Polyanthi Papanastasiou; Katerina Gioti; Petros Pavlopoulos; Kalliopi Diamantopoulou; Eupthemia Thomas-Tsagli; Konstantinos Xiromeritis; Efstratios Patsouris
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

10.  Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.

Authors:  Jacques B de Kok; Rian W Roelofs; Belinda A Giesendorf; Jeroen L Pennings; Erwin T Waas; Ton Feuth; Dorine W Swinkels; Paul N Span
Journal:  Lab Invest       Date:  2005-01       Impact factor: 5.662

View more
  9 in total

Review 1.  The Hippo pathway: an emerging role in urologic cancers.

Authors:  Bekir Cinar; Esma Alp; Marwah Al-Mathkour; Ava Boston; Abdulrahman Dwead; Kezhan Khazaw; Alexis Gregory
Journal:  Am J Clin Exp Urol       Date:  2021-08-25

2.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

3.  Tissue Profile of CDK4 and STAT3 as Possible Innovative Therapeutic Targets in Urinary Bladder Cancer.

Authors:  Tarek Aboushousha; Olfat Hammam; Ahmed Aref; Amira Kamel; Mohamed Badawy; Amr Abdel Hamid
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

4.  STAT3 expression is a prognostic marker in upper urinary tract urothelial carcinoma.

Authors:  Kyosuke Matsuzaki; Kazutoshi Fujita; Yujiro Hayashi; Makoto Matsushita; Satoshi Nojima; Kentaro Jingushi; Taigo Kato; Atsunari Kawashima; Takeshi Ujike; Akira Nagahara; Motohide Uemura; Ryoichi Imamura; Seiji Yamaguchi; Hiroaki Fushimi; Hiroshi Miyamoto; Eiichi Morii; Norio Nonomura
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

5.  Quinalizarin induces ROS‑mediated apoptosis via the MAPK, STAT3 and NF‑κB signaling pathways in human breast cancer cells.

Authors:  Yan-Qing Zang; Yan-Yu Feng; Ying-Hua Luo; Yu-Qing Zhai; Xue-Ying Ju; Yu-Chao Feng; Ya-Nan Sheng; Jia-Ru Wang; Chang-Qing Yu; Cheng-Hao Jin
Journal:  Mol Med Rep       Date:  2019-10-02       Impact factor: 2.952

6.  Paeonol Suppresses Proliferation and Motility of Non-Small-Cell Lung Cancer Cells by Disrupting STAT3/NF-κB Signaling.

Authors:  Lei Zhang; Wen-Xu Chen; Ling-Li Li; Yu-Zhu Cao; Ya-Di Geng; Xiao-Jun Feng; Ai-Yun Wang; Zhao-Lin Chen; Yin Lu; Ai-Zong Shen
Journal:  Front Pharmacol       Date:  2020-11-12       Impact factor: 5.810

7.  Differential expression of NF-κB heterodimer RelA/p50 in human urothelial carcinoma.

Authors:  Sankari Durairajan; Charles Emmanuel Jebaraj Walter; Mary Divya Samuel; Dinesh Palani; Dicky John Davis G; George Priya Doss C; Sneha Pasupati; Thanka Johnson
Journal:  PeerJ       Date:  2018-09-13       Impact factor: 2.984

8.  RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-κB pathway.

Authors:  Jian-Ye Liu; Qing-Hai Zeng; Pei-Guo Cao; Dan Xie; Xin Chen; Fei Yang; Le-Ye He; Ying-Bo Dai; Jing-Jing Li; Xiao-Ming Liu; Hong-Liang Zeng; Yi-Xin Zhu; Lian Gong; Yan Cheng; Jian-Da Zhou; Jun Hu; Hao Bo; Zhen-Zhou Xu; Ke Cao
Journal:  Br J Cancer       Date:  2018-06-05       Impact factor: 7.640

9.  STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.

Authors:  Sruthi V Hindupur; Sebastian C Schmid; Jana Annika Koch; Ahmed Youssef; Eva-Maria Baur; Dongbiao Wang; Thomas Horn; Julia Slotta-Huspenina; Juergen E Gschwend; Per Sonne Holm; Roman Nawroth
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.